T Cell Acute Lymphoblastic Leukemia clinical trials

Explore recruiting t cell acute lymphoblastic leukemia clinical trials.

Recruiting t cell acute lymphoblastic leukemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

T Cell Acute Lymphoblastic Leukemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A PRECISION MEDICINE RANDOMIZED TRIAL FOR PATIENTS WITH RELAPSED OR REFRACTORY T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA BASED ON A FUNCTIONAL APPROACH. ALL-TARGET TRIAL

Germany, France, Czechia, Netherlands, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Safety and efficacy of hCD1a-CAR T (OC-1) therapy, in patients with relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL)_CARxALL

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Daratumumab in adults with Very High-Risk T-Lineage Acute Lymphoblastic Leukemia (ALL) Treated According to the ALL National Treatment Program (DARATALL-VHR)- GIMEMA ALL3024

Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Long-term Follow-up study for relapsed/refractory (R/R) T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LL) patients previously treated with OC-1 cells.

Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase I/II study of anti-CD7 Chimeric Antigen Receptor-Expressing T cells in pediatric patients/young adult affected by relapsed/refractory CD7+ T-cell Acute Lymphoblastic Leukemia/Lymphoma

Italy

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A multicenter, single-arm phase II study to assess the safety, tolerability, and efficacy of Isatuximab in adult patients with cytologic or molecular relapsed/refractory CD38 positive T-cell acute lymphoblastic leukemia

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

T Cell Acute Lymphoblastic Leukemia trials by city

T Cell Acute Lymphoblastic Leukemia in Toronto T Cell Acute Lymphoblastic Leukemia in Vancouver T Cell Acute Lymphoblastic Leukemia in Montreal T Cell Acute Lymphoblastic Leukemia in Calgary T Cell Acute Lymphoblastic Leukemia in Edmonton T Cell Acute Lymphoblastic Leukemia in Ottawa T Cell Acute Lymphoblastic Leukemia in Winnipeg T Cell Acute Lymphoblastic Leukemia in Quebec City T Cell Acute Lymphoblastic Leukemia in Hamilton T Cell Acute Lymphoblastic Leukemia in Kitchener T Cell Acute Lymphoblastic Leukemia in London T Cell Acute Lymphoblastic Leukemia in Halifax T Cell Acute Lymphoblastic Leukemia in New York T Cell Acute Lymphoblastic Leukemia in Los Angeles T Cell Acute Lymphoblastic Leukemia in Chicago T Cell Acute Lymphoblastic Leukemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease